Erica B. Schleifman, Ph.D.
Affiliations: | 2011 | Yale University, New Haven, CT |
Area:
Genetics, Molecular Biology, Cell BiologyGoogle:
"Erica Schleifman"Parents
Sign in to add mentor| Peter M. Glazer | grad student | 2011 | Yale | |
| (Targeted Inactivation of the CCR5 Gene via PNA-induced Homologous Recombination.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Socinski MA, Paul SM, Yun C, et al. (2019) Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC Cancer Research. 79 |
| Li Y, Sun JX, Skoletsky J, et al. (2018) Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii24 |
| Clark TA, Chung JH, Kennedy M, et al. (2018) Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. The Journal of Molecular Diagnostics : Jmd |
| Lieber DS, White E, Silterra J, et al. (2018) Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC Cancer Immunology Research. 6 |
| Fabrizio D, Lieber D, Malboeuf C, et al. (2018) Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab Cancer Research. 78: 5706-5706 |
| Sun JX, Li Y, Milbury C, et al. (2018) Abstract 4757: A clinically validated comprehensive companion diagnostic platform for care of patients with advanced cancer Cancer Research. 78: 4757-4757 |
| Spoerke J, Schleifman E, Clark T, et al. (2017) Abstract P6-07-08: The complete spectrum ofESR1mutations from 7590 breast cancer tumor samples Cancer Research. 77 |
| Fabrizio D, Malboeuf C, Lieber D, et al. (2017) Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST) Annals of Oncology. 28: v27 |
| Stephens P, Clark TA, Kennedy M, et al. (2016) Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors. Journal of Clinical Oncology. 34: e23049-e23049 |
| Clark TA, Kennedy M, He J, et al. (2016) Abstract 3965: Rigorous validation of a clinical circulating tumor DNA assay for cancer molecular profiling Cancer Research. 76: 3965-3965 |